Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Donald Trump, at 78, is aggressively pursuing his second term, marked by significant policy changes and a noticeable physical ...

Rumours are swirling that Donald Trump has been jacking up with Ozempic to shed some pounds - after denying poor people the ...

BUFFALO, N.Y. — In January, Nicole Albanese, PharmD, clinical associate professor of pharmacy practice in the University at ...

It’s a Beast of a time in Washington. Donald Trump’s D.C. reality show is full of new characters, plot twists, and ...

Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...

The Centers for Medicare & Medicaid Services will begin holding closed-door meetings this week with patients who use the 15 ...

Independence Health Group, the parent company of Independence Blue Cross, spent $500 million last year to provide ...

Meanwhile, Stat reports that in Ireland — a global pharmaceutical hub — potential U.S. tariffs are raising concerns. Also in the news: Novo Nordisk, PBM legislation in statehouses, same-day ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...